Glassy Mountain Advisors Inc. Buys 4,151 Shares of Merck & Co., Inc. (NYSE:MRK)

Glassy Mountain Advisors Inc. increased its stake in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 11.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,304 shares of the company’s stock after purchasing an additional 4,151 shares during the quarter. Merck & Co., Inc. comprises about 1.7% of Glassy Mountain Advisors Inc.’s portfolio, making the stock its 20th biggest position. Glassy Mountain Advisors Inc.’s holdings in Merck & Co., Inc. were worth $3,225,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. Sheets Smith Wealth Management raised its position in shares of Merck & Co., Inc. by 0.5% in the 4th quarter. Sheets Smith Wealth Management now owns 24,741 shares of the company’s stock valued at $1,896,000 after buying an additional 124 shares in the last quarter. Ritter Daniher Financial Advisory LLC raised its position in shares of Merck & Co., Inc. by 33.9% in the 4th quarter. Ritter Daniher Financial Advisory LLC now owns 517 shares of the company’s stock valued at $40,000 after buying an additional 131 shares in the last quarter. First Interstate Bank raised its position in shares of Merck & Co., Inc. by 1.6% in the 4th quarter. First Interstate Bank now owns 8,509 shares of the company’s stock valued at $653,000 after buying an additional 134 shares in the last quarter. Mckinley Capital Management LLC Delaware raised its position in shares of Merck & Co., Inc. by 0.9% in the 4th quarter. Mckinley Capital Management LLC Delaware now owns 14,621 shares of the company’s stock valued at $1,121,000 after buying an additional 135 shares in the last quarter. Finally, Capital City Trust Co. FL increased its position in Merck & Co., Inc. by 4.2% during the 4th quarter. Capital City Trust Co. FL now owns 3,376 shares of the company’s stock worth $259,000 after purchasing an additional 137 shares in the last quarter. 72.88% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE MRK opened at $89.16 on Thursday. The firm has a 50 day moving average price of $88.75 and a two-hundred day moving average price of $82.17. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.14 and a current ratio of 1.40. Merck & Co., Inc. has a 52-week low of $70.89 and a 52-week high of $94.92. The stock has a market cap of $225.47 billion, a P/E ratio of 15.95, a price-to-earnings-growth ratio of 1.19 and a beta of 0.36.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The company reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $1.81 by $0.33. Merck & Co., Inc. had a net margin of 26.27% and a return on equity of 47.86%. The company had revenue of $15.90 billion for the quarter, compared to analyst estimates of $14.64 billion. During the same period in the prior year, the firm posted $1.40 EPS. The company’s quarterly revenue was up 31.6% on a year-over-year basis. Analysts predict that Merck & Co., Inc. will post 7.32 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 8th. Stockholders of record on Wednesday, June 15th will be paid a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date of this dividend is Tuesday, June 14th. Merck & Co., Inc.’s dividend payout ratio is currently 49.37%.

MRK has been the subject of a number of research analyst reports. Morgan Stanley lowered their price objective on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Mizuho initiated coverage on shares of Merck & Co., Inc. in a research report on Friday, April 1st. They set a “buy” rating and a $100.00 price objective for the company. StockNews.com initiated coverage on shares of Merck & Co., Inc. in a research report on Thursday, March 31st. They set a “strong-buy” rating for the company. SVB Leerink reiterated an “outperform” rating and set a $102.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, June 6th. Finally, Barclays upped their price objective on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 12th. Seven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.60.

Merck & Co., Inc. Company Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.